// App-Quantinova.ai

2795 : Interim Results of a Multicenter, Single-Arm Study to Assess Blinatumomab in Adult Patients (pts) with Minimal Residual Disease (MRD) of B-Precursor (BCP) Acute Lymphoblastic Leukemia (GMALL-MOLACT1-BLINA)

Researchers

Presenter

  • Nicola Goekbuget

Principal Investigators

  • Stefan Schwartz

  • Andreas Httmann

  • Christoph Faul

  • Simon Raffel

  • Andreas Viardot

  • Walter Fiedler

  • Nael Alakel

  • Matthias Stelljes

  • Marion Subklewe

  • Ralph Wsch

  • Sonja Martin

  • Wolfram Jung

  • Vladan Vucinic

  • Mustafa Kondakci

  • Lars R. Fransecky

  • Daniela Heidenreich

  • Knut Wendelin

  • Julian Hermann

  • Hubert Serve

  • Ralf C Bargou

  • Max S. Topp

  • Monika Brggemann

Medical Centers

  • University Hospital, Department of Medicine II, Hematology/Oncology, Head of Study Center Depart of Medicine II, Hematology/Oncology Goethe University Hospital, Frankfurt, Germany

  • University Hospital, Department of Medicine II, Hematology/Oncology, Goethe University, Frankfurt, Germany

  • Department of Rheumatology and Clinical Immunology, Charite - Universitatsmedizin Berlin, Berlin, Germany

  • Department of Hematology, University Hospital, Essen, NRW, Germany

  • University of Tubingen, Tubingen, Germany

  • Departement of Nuclear Medicine, University of Heidelberg, Heidelberg, Germany

  • Department of Internal Medicine, University Hospital of Ulm, Ulm, Germany

  • Department of Oncology, Hematology and Bone Marrow Transplantation With Section Pneumology, Hubertus Wald University Cancer Center, University Medical Center Hamburg-Eppendorf, Hamburg, Germany

  • Essen University Hospital, Essen, Germany

  • Department of Nuclear Medicine, University Hospital Muenster, Muenster, Germany

  • Department of Medicine III, University Hospital Grosshadern/LMU, Munich, Germany

  • Department of Medicine, Division Hematology and Oncology, University of Freiburg Medical Center, Freiburg, Germany

  • Department of Hematology and Oncology, Katharinenhospital, Stuttgart, Germany

  • Dept. of Hematology and Oncology, Universitätsklinikum Göttingen, Göttingen, Germany

  • Department of Hematology, University of Leipzig, Leipzig, Germany

  • Department of Hematology, Oncology and Clinical Immunology, Universitaetsklinikum Duesseldorf, Duesseldorf, Germany,

  • University Hospital Schleswig-Holstein, Lubeck, Germany

  • UMM University Medical Center Mannheim, University of Heidelberg, Mannheim, DEU

  • Klinikum Nurnberg Nord, Nurnberg, Germany

  • Comprehensive Cancer Center Mainfranken, Universitaetsklinikum Wuerzburg, Wuerzburg, Germany

  • Medizinische Klinik und Poliklinik II, Universitatsklinikum Wurzburg, Wurzburg, Germany

  • Medical Department II of Hematology and Oncology, University Hospitals of Schleswig Holstein, Campus Kiel, Germany.

Locations

  • Germany

Companies

  • N/A

Study Components

Therapeutic Area

  • Autoimmune (AI)

Disease

  • Acute lymphoblastic leukemia

  • Graft-versus-host disease

Biomarkers

  • Breakpoint Cluster Region

  • Cluster of Differentiation 19

  • Cluster of Differentiation 2AP

  • T-cell receptor

Drug/Treatment

  • Blinatumomab

Outcome

  • N/A

Study Design

  • Single Arm

  • Multicenteric

Phase

  • NA

Study Id's

  • NCT03109093

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved